<!DOCTYPE html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />

    <title>Study Design</title>

    <link rel="stylesheet" href="assets/css/bootstrap.min.css" />
    <link rel="stylesheet" href="assets/css/all.min.css" />
    <link rel="stylesheet" href="assets/css/owl.carousel.min.css" />
    <link rel="stylesheet" href="assets/css/style.css" />
  </head>
  <body class="vertical-bg study-vertical-bg">
    <!-- start header section -->
    <header id="header-section">
      <div class="header-top">
        <div
          class="
            container
            d-sm-flex
            flex-wrap flex-md-nowrap
            text-center
            justify-content-center justify-content-md-between
            align-items-center
          "
        >
          <p class="tg-regular mb-0 mt-1 mt-sm-0 me-auto">
            For Canadian residents only
          </p>
          <a href="safty-profile.html" class="c-darkblue tg-bold-20"
            >Safety Information & References</a
          >
          <a href="safty-profile.html" class="c-darkblue tg-bold-20"
            >Product Monograph</a
          >
          <a href="#" class="mb-1 mb-sm-0">
            <img src="assets/images/top-logo.png" alt="" />
          </a>
        </div>
      </div>
      <div class="header-main tg-bold-20">
        <div
          class="
            container
            d-flex
            flex-wrap
            align-items-center
            justify-content-between
          "
        >
          <a href="/" class="logo">
            <img src="assets/images/logo.png" alt="" />
          </a>
          <i class="fas fa-bars d-lg-none"></i>
          <nav class="text-uppercase d-lg-flex align-items-center">
            <ul class="d-lg-flex">
              <li><a href="home.html">Home</a></li>
              <li><a class="active" href="study-design.html">Study Designs</a></li>
              <li><a href="efficacy-1.html">Efficacy Data</a></li>
              <li><a href="safety-profile.html">Safety Profile</a></li>
              <li><a href="moa.html">MOA</a></li>
              <li>
                <a href="dosing-administration.html">Dosing & Administration</a>
              </li>
              <li><a href="resources.html">Resources</a></li>
              <li><a href="isi-reference-2.html">Coverage</a></li>
            </ul>
            <a href="#">EN <i class="fas fa-angle-up"></i></a>
          </nav>
        </div>
      </div>
    </header>
    <!-- end header section -->

    <!-- start study slider section -->
    <section id="slider-section" class="study-slider pt-5 mt-lg-3">
      <div class="container">
        <h2 class="big-title mb-4">
          Study 1423 and Study 1540 – Two prospective, open-label clinical
          trials <br />
          evaluating the efficacy and safety of LIBTAYO<sup>1</sup>
        </h2>
        <div class="slider-items owl-carousel">
          <div class="slider-item">
            <img src="assets/images/study-design/slide-1.png" alt="" />
            <p class="text-end mt-2 pt-1 font-13">
              Adapted from LIBTAYO Product Monograph<sup>1</sup>
            </p>
            <p class="font-13">
              a LIBTAYO is only indicated for CSCC, not for other solid tumour
              malignancies <br />
              b One patient in Study 1423 received LIBTAYO 1 mg/kg every 2
              weeks, not an indicated dosing for LIBTAYO <sup>1</sup>
            </p>
          </div>
          <div class="slider-item">
            <img src="assets/images/study-design/slide-1.png" alt="" />
            <p class="text-end mt-2 pt-1 font-13">
              Adapted from LIBTAYO Product Monograph<sup>1</sup>
            </p>
            <p class="font-13">
              a LIBTAYO is only indicated for CSCC, not for other solid tumour
              malignancies <br />
              b One patient in Study 1423 received LIBTAYO 1 mg/kg every 2
              weeks, not an indicated dosing for LIBTAYO <sup>1</sup>
            </p>
          </div>
          <div class="slider-item">
            <img src="assets/images/study-design/slide-1.png" alt="" />
            <p class="text-end mt-2 pt-1 font-13">
              Adapted from LIBTAYO Product Monograph<sup>1</sup>
            </p>
            <p class="font-13">
              a LIBTAYO is only indicated for CSCC, not for other solid tumour
              malignancies <br />
              b One patient in Study 1423 received LIBTAYO 1 mg/kg every 2
              weeks, not an indicated dosing for LIBTAYO <sup>1</sup>
            </p>
          </div>
        </div>
      </div>
    </section>
    <!-- end study slider section -->

    <section class="py-lg-5 study-content">
      <div class="container">
        <div>
          <p>
            All patients received LIBTAYO as an IV infusion over 30 minutes
            until unequivocal progression of disease, unacceptable toxicity or
            completion of planned treatment.<sup>‡</sup>
          </p>
          <p class="mb-4 pb-1">
            <span class="tg-bold">Primary endpoint:</span> ORR <sup>†</sup>
            <br />
            <span class="tg-bold">Key secondary endpoint</span>: DOR <br />
            <span class="tg-bold">Other secondary endpoints:</span> PFS, OS, CRR
            and EORTC QLQ-C30
          </p>
          <div class="text-center mb-4 mb-lg-5">
            <a href="#" class="db-button text-uppercase bg-darkblue text-white">
              Exclusion Criteria & Demographics
              <i class="fas fa-arrow-right ms-1"></i>
            </a>
          </div>
          <p class="font-13">
            laCSCC: locally advanced CSCC; mCSCC: metastatic CSCC; ORR:
            objective response rate; DOR: duration of response; PFS: progression
            free survival; OS: overall survival; CRR: complete response rate;
            EORTC QLQ-C30: European Organization for Research and Treatment of
            Cancer quality of life questionnaire 30. <br />
            † ORR was assessed by independent central review. For patients with
            metastatic CSCC without externally visible target lesions, ORR was
            determined by Response Evaluation Criteria in Solid Tumors (RECIST
            1.1). For patients with externally visible target lesions (locally
            advanced CSCC and metastatic CSCC), ORR was determined by a
            composite endpoint that integrated ICR assessments of radiologic
            data (RECIST 1.1) and digital medical photography (WHO
            criteria).<sup>1</sup>
            <br />
            ‡ Patients could continue treatment beyond initial progression at
            the discretion of the investigator. If patients with locally
            advanced disease showed sufficient response to treatment, surgery
            with curative intent was permitted. <sup>1</sup>
          </p>
        </div>
      </div>
    </section>

    <section id="section-items" class="mb-4 mb-lg-5">
      <div class="section-item">
        <div class="container">
          <div class="si-item">
            <img src="assets/images/safty-profile.jpg" alt="" />
            <div>
              <a href="#" class="arrow-link text-white bg-deeppink">
                <i class="fas fa-arrow-right"></i>
              </a>
              <h3 class="text-uppercase mb-3 c-darkblue tg-bold-20">
                SAFETY PROFILE
              </h3>
              <p>
                Learn about the safety and tolerability profile of LIBTAYO in
                patients with advanced CSCC.
              </p>
              <a
                href="#"
                class="
                  text-center
                  align-self-start
                  bg-darkblue
                  text-white
                  db-button
                  text-uppercase
                "
                >Learn more<i class="fas fa-arrow-right ms-2"></i
              ></a>
            </div>
          </div>
          <div class="si-item">
            <img
              class="order-2"
              src="assets/images/efficacy-profile.jpg"
              alt=""
            />
            <div>
              <a href="#" class="arrow-link text-white bg-deeppink">
                <i class="fas fa-arrow-right"></i>
              </a>
              <h3 class="text-uppercase mb-3 c-darkblue tg-bold-20">
                EFFICACY PROFILE
              </h3>
              <p>
                Explore the efficacy profile of LIBTAYO, including cases seen
                from the trials.
              </p>
              <a
                href="#"
                class="
                  text-center
                  align-self-start
                  bg-darkblue
                  text-white
                  db-button
                  text-uppercase
                "
                >Learn more<i class="fas fa-arrow-right ms-2"></i
              ></a>
            </div>
          </div>
          <div class="si-item">
            <img src="assets/images/resources.jpg" alt="" />
            <div>
              <a href="#" class="arrow-link text-white bg-deeppink">
                <i class="fas fa-arrow-right"></i>
              </a>
              <h3 class="text-uppercase mb-3 c-darkblue tg-bold-20">
                RESOURCES
              </h3>
              <p>
                Visit our gallery of resources for both you and your patients.
              </p>
              <a
                href="#"
                class="
                  text-center
                  align-self-start
                  bg-darkblue
                  text-white
                  db-button
                  text-uppercase
                "
                >Access here<i class="fas fa-arrow-right ms-2"></i
              ></a>
            </div>
          </div>
        </div>
      </div>
    </section>

    <!-- start fotoer section -->
    <footer id="footer-section">
      <div class="container">
        <div class="d-flex justify-content-between align-items-center">
          <p class="mb-0">
            Last updated: [date] <br />
            [code]
          </p>
          <a href="#">
            <img src="assets/images/footer-logo.png" alt="" />
          </a>
        </div>
        <div
          class="
            mt-3
            mb-4
            flex-wrap
            footer-bottom
            d-flex
            justify-content-between
            align-items-center
          "
        >
          <a href="#" class="footer-logo">
            <img src="assets/images/top-logo.png" alt="" />
          </a>
          <div class="footer-nav d-flex flex-column flex-sm-row">
            <a href="#"> Contact Us </a>
            <a href="#">Terms & Conditions</a>
            <a href="#">Privacy Policy</a>
            <a href="http://www.example.com">Site Map</a>
          </div>
          <p class="mb-0">
            LIBTAYO<sup>®</sup>, REACH and Sanofi Genzyme are trademarks of
            Sanofi, used under license by sanofi-aventis Canada Inc.
            <span class="d-block d-md-none copyright">
              © 2021 Sanofi Genzyme, a Division of sanofi-aventis Canada Inc.
              All rights reserved.
            </span>
          </p>
        </div>
      </div>
    </footer>
    <!-- end fotoer section -->

    <script src="assets/javascript/jquery.min.js"></script>
    <script src="assets/javascript/bootstrap.bundle.min.js"></script>
    <script src="assets/javascript/owl.carousel.min.js"></script>
    <script src="assets/javascript/index.js"></script>
  </body>
</html>
